Eric Johannsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric Johannsen has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Jenny E. Gumperz
Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
20 shared publications - Dana Carina Baiu
Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
19 shared publications - Huy Q. Dinh
McArdle Laboratory for Cancer Research, Department of Oncology, Carbone Cancer Center, University of Wisconsin-Madison, Madison, USA
19 shared publications - Joshua Brand
University of Wisconsin 2 McArdle Laboratory for Cancer Research, Department of Oncology Madison, Wisconsin
19 shared publications - Kelsey A. Smith
Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
19 shared publications - Makoto Ohashi
Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
19 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (22)
Epstein–Barr virus (EBV) infection causes human germinal center B cell–derived lymphomas in the absence of EBNA2 expression
EBV is associated with human B cell lymphomas, including Burkitt lymphomas (BLs), diffuse large B cell lymphomas (DLBCLs), Hodgkin lymphomas (HLs), and Plasmablastic lymphomas (PLs). EBV+ lymphomas in immunocompetent humans are usually derived from germinal center (GC)-experienced B cells and have stringent latency forms that do not express the viral transforming protein, EBNA2. Human EBV+ lymphomas that lack EBNA2 expression are largely driven by the viral LMP1 and LMP2A proteins, which activate NF-κB and B cell receptor-like signaling, respectively, or by Myc translocations. However, EBNA2 is required for EBV-mediated transformation of B cells in vitro and there is currently no model system for studying how EBV transforms human GC-derived B cells into lymphomas in vivo in the absence of EBNA2 expression or Myc translocation. Here, we show that human tonsil GC B cells (GCBs) infected with an EBNA2-deleted EBV mutant proliferate on a CD40L/IL21-expressing feeder layer and form lymphomas in NSG mice that resemble human DLBCLs (both ABC and GCB subtypes) and PLs. These EBV-induced lymphomas occur in the absence of Myc overexpression, often have normal karyotypes, and do not contain mutations in cellular genes (including p53) commonly mutated in uninfected human DLBCLs. Using this model system, we show that LMP2A induces plasmablast differentiation, increases expression of genes involved in lymphocyte mobility and trafficking and enhances tumor invasiveness in vivo. This new model system can thus be used to define roles of viral and cellular proteins in EBV-induced human GCB-derived lymphomas that lack EBNA2 expression.
- 26 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (22)
Open AccessEpstein–Barr virus (EBV) infection causes human germinal center B cell–derived lymphomas in the absence of EBNA2 expression
EBV is associated with human B cell lymphomas, including Burkitt lymphomas (BLs), diffuse large B cell lymphomas (DLBCLs), Hodgkin lymphomas (HLs), and Plasmablastic lymphomas (PLs). EBV+ lymphomas in immunocompetent humans are usually derived from germinal center (GC)-experienced B cells and have stringent latency forms that do not express the viral transforming protein, EBNA2. Human EBV+ lymphomas that lack EBNA2 expression are largely driven by the viral LMP1 and LMP2A proteins, which activate NF-κB and B cell receptor-like signaling, respectively, or by Myc translocations. However, EBNA2 is required for EBV-mediated transformation of B cells in vitro and there is currently no model system for studying how EBV transforms human GC-derived B cells into lymphomas in vivo in the absence of EBNA2 expression or Myc translocation. Here, we show that human tonsil GC B cells (GCBs) infected with an EBNA2-deleted EBV mutant proliferate on a CD40L/IL21-expressing feeder layer and form lymphomas in NSG mice that resemble human DLBCLs (both ABC and GCB subtypes) and PLs. These EBV-induced lymphomas occur in the absence of Myc overexpression, often have normal karyotypes, and do not contain mutations in cellular genes (including p53) commonly mutated in uninfected human DLBCLs. Using this model system, we show that LMP2A induces plasmablast differentiation, increases expression of genes involved in lymphocyte mobility and trafficking and enhances tumor invasiveness in vivo. This new model system can thus be used to define roles of viral and cellular proteins in EBV-induced human GCB-derived lymphomas that lack EBNA2 expression.
- Open Access
Integrating Epstein-Barr virus (EBV) status into diffuse large B cell lymphoma (DLBCL) genetics
Diffuse large B-cell lymphoma (DLBCL), the most common aggressive lymphoma, encompasses histologically similar but genetically distinct cancers. Recent genetic studies have defined at least six molecular subtypes, yet none account for Epstein-Barr virus (EBV), despite 5-15% of DLBCLs being EBV-associated. By reanalyzing published whole-exome and RNA-sequencing data from 481 tumors, we identified 19 EBV-positive cases. These were significantly enriched in the BN2 subtype (6/19), while most (11/19) remained unclassified. In BN2 tumors, several subtype-defining mutations were reduced in frequency among EBV-positive cases, supporting the hypothesis that EBV oncogenes substitute for specific cellular alterations and may confound DLBCL classification algorithms. Extending our analysis to cell lines, we found that the widely used Val cell line harbors the B95-8 laboratory EBV strain; other EBV-positive lines appeared authentic but modeled only non-BN2 subtypes and expressed an atypical viral latency III program, whereas some DLBCL tumors expressed the atypical latency III program and others latency I or II. Together, these findings demonstrate that EBV-positive DLBCL, like DLBCL itself, is not a single disease, and that current in vitro models only partially capture its biological heterogeneity. Key points: EBV-positive DLBCL is not a single disease and EBV status can impact genetic-based classifications. Current EBV-positive DLBCL cell lines do not adequately capture tumor complexity; we determined that Val is a problematic cell line.
Open AccessIntegrating Epstein-Barr virus (EBV) status into diffuse large B cell lymphoma (DLBCL) genetics
Diffuse large B-cell lymphoma (DLBCL), the most common aggressive lymphoma, encompasses histologically similar but genetically distinct cancers. Recent genetic studies have defined at least six molecular subtypes, yet none account for Epstein-Barr virus (EBV), despite 5-15% of DLBCLs being EBV-associated. By reanalyzing published whole-exome and RNA-sequencing data from 481 tumors, we identified 19 EBV-positive cases. These were significantly enriched in the BN2 subtype (6/19), while most (11/19) remained unclassified. In BN2 tumors, several subtype-defining mutations were reduced in frequency among EBV-positive cases, supporting the hypothesis that EBV oncogenes substitute for specific cellular alterations and may confound DLBCL classification algorithms. Extending our analysis to cell lines, we found that the widely used Val cell line harbors the B95-8 laboratory EBV strain; other EBV-positive lines appeared authentic but modeled only non-BN2 subtypes and expressed an atypical viral latency III program, whereas some DLBCL tumors expressed the atypical latency III program and others latency I or II. Together, these findings demonstrate that EBV-positive DLBCL, like DLBCL itself, is not a single disease, and that current in vitro models only partially capture its biological heterogeneity. Key points: EBV-positive DLBCL is not a single disease and EBV status can impact genetic-based classifications. Current EBV-positive DLBCL cell lines do not adequately capture tumor complexity; we determined that Val is a problematic cell line.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S7. Fold-expansion of CD4 or CD8 T cells from HNSCC patient blood.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S7. Fold-expansion of CD4 or CD8 T cells from HNSCC patient blood.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S5. Detection of immunotherapeutic iNKT cells and DCs after injection into tumor bearing mice.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S5. Detection of immunotherapeutic iNKT cells and DCs after injection into tumor bearing mice.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S1. Analysis of tumor mass and immunotherapy effects as a function of mouse sex.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S1. Analysis of tumor mass and immunotherapy effects as a function of mouse sex.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Movie S3 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S3 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Differentially expressed genes
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Differentially expressed genes
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S9. Comparison of anti-tumor immunotherapeutic effect of iNKT-DCs generated using polyclonal vs. clonal CD4+ iNKT cells.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S9. Comparison of anti-tumor immunotherapeutic effect of iNKT-DCs generated using polyclonal vs. clonal CD4+ iNKT cells.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Movie S5 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Paired iNKT-DC migration example 1
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S5 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Paired iNKT-DC migration example 1
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Data from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Invariant NK T (iNKT) cells are a conserved T-lymphocyte population capable of acting on dendritic cells (DC) to potently amplify downstream immune responses. However, the processes underlying such iNKT adjuvancy remain poorly understood. In this study, we showed that allogeneic human CD4+ iNKT cells form stably adhered bi-cellular complexes with monocyte-derived DCs that migrated together as pairs and showed extended DC calcium signaling. Compared with DCs treated with the synthetic adjuvant monophosphoryl lipid A, DCs complexed with iNKT cells had elevated expression of MHC class I and multiple costimulatory molecules, including 4-1BBL, OX40L, and IL15Rα, whereas the iNKT cells expressed CD70. Consistent with this distinctive costimulatory profile, iNKT–DC complexes were efficient activators of CD8+ T cells. Administering iNKT–DC complexes as a cellular immunotherapy in a xenograft model of aggressive human B-cell lymphoma resulted in rapid reduction in tumor mass, antigen-specific B-cell clearance, and transcriptional activation indicative of enhanced T-cell proliferation and effector responses. iNKT–DC immunotherapy was effective at late stages of tumor progression that were refractory to immune checkpoint blockade immunotherapy, suggesting that the consortium of activating signals provided by iNKT–DC complexes rejuvenates exhausted antitumor immunity. Finally, allogeneic CD4+ iNKT cells formed similar complexes with monocyte-derived DCs from patients with head and neck cancer and promoted tumor antigen–dependent CD8+ T-cell activation. These results show that monocyte-derived DCs paired with allogeneic CD4+ iNKT cells act as a potent antitumor cellular immunotherapy that activates antigen-specific CD8+ T-cell immunity.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Invariant NK T (iNKT) cells are a conserved T-lymphocyte population capable of acting on dendritic cells (DC) to potently amplify downstream immune responses. However, the processes underlying such iNKT adjuvancy remain poorly understood. In this study, we showed that allogeneic human CD4+ iNKT cells form stably adhered bi-cellular complexes with monocyte-derived DCs that migrated together as pairs and showed extended DC calcium signaling. Compared with DCs treated with the synthetic adjuvant monophosphoryl lipid A, DCs complexed with iNKT cells had elevated expression of MHC class I and multiple costimulatory molecules, including 4-1BBL, OX40L, and IL15Rα, whereas the iNKT cells expressed CD70. Consistent with this distinctive costimulatory profile, iNKT–DC complexes were efficient activators of CD8+ T cells. Administering iNKT–DC complexes as a cellular immunotherapy in a xenograft model of aggressive human B-cell lymphoma resulted in rapid reduction in tumor mass, antigen-specific B-cell clearance, and transcriptional activation indicative of enhanced T-cell proliferation and effector responses. iNKT–DC immunotherapy was effective at late stages of tumor progression that were refractory to immune checkpoint blockade immunotherapy, suggesting that the consortium of activating signals provided by iNKT–DC complexes rejuvenates exhausted antitumor immunity. Finally, allogeneic CD4+ iNKT cells formed similar complexes with monocyte-derived DCs from patients with head and neck cancer and promoted tumor antigen–dependent CD8+ T-cell activation. These results show that monocyte-derived DCs paired with allogeneic CD4+ iNKT cells act as a potent antitumor cellular immunotherapy that activates antigen-specific CD8+ T-cell immunity.